<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2017//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_170101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">28502102</PMID>
        <DateCreated>
            <Year>2017</Year>
            <Month>05</Month>
            <Day>14</Day>
        </DateCreated>
        <DateRevised>
            <Year>2017</Year>
            <Month>05</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1582-4934</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2017</Year>
                        <Month>May</Month>
                        <Day>13</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cellular and molecular medicine</Title>
                <ISOAbbreviation>J. Cell. Mol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Functional analysis by minigene assay of putative splicing variants found in Bardet-Biedl syndrome patients.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.13147</ELocationID>
            <Abstract>
                <AbstractText>Bardet-Biedl syndrome (BBS) and Alström syndrome (ALMS) are rare diseases belonging to the group of ciliopathies. Although mutational screening studies of BBS/ALMS cohorts have been extensively reported, little is known about the functional effect of those changes. Thus, splicing variants are estimated to represent 15% of disease-causing mutations, and there is growing evidence that many exonic changes are really splicing variants misclassified. In this study, we aimed to analyse for the first time several variants in BBS2, ARL6/BBS3, BBS4 and ALMS1 genes predicted to produce aberrant splicing by minigene assay. We found discordance between bioinformatics analysis and experimental data when comparing wild-type and mutant constructs. Remarkably, we identified nonsense variants presumably resistant to nonsense-mediated decay, even when a premature termination codon would be introduced in the second amino acid (p.(G2*) mutation in ARL6/BBS3 gene). As a whole, we report one of the first functional studies of BBS/ALMS1 variants using minigene assay, trying to elucidate their role in disease. Functional studies of variants identified in BBS and ALMS patients are essential for their proper classification and subsequent genetic counselling and could also be the start point for new therapeutic approaches, currently based only on symptomatic treatment.</AbstractText>
                <CopyrightInformation>© 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &amp; Sons Ltd and Foundation for Cellular and Molecular Medicine.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Álvarez-Satta</LastName>
                    <ForeName>María</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Grupo de Biomarcadores Moleculares (BB1), Departamento de Bioquímica, Genética e Inmunología, Facultad de Biología, Universidad de Vigo, Vigo, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castro-Sánchez</LastName>
                    <ForeName>Sheila</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Grupo de Biomarcadores Moleculares (BB1), Departamento de Bioquímica, Genética e Inmunología, Facultad de Biología, Universidad de Vigo, Vigo, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pousada</LastName>
                    <ForeName>Guillermo</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Grupo de Biomarcadores Moleculares (BB1), Departamento de Bioquímica, Genética e Inmunología, Facultad de Biología, Universidad de Vigo, Vigo, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valverde</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7024-1657</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Grupo de Biomarcadores Moleculares (BB1), Departamento de Bioquímica, Genética e Inmunología, Facultad de Biología, Universidad de Vigo, Vigo, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Cell Mol Med</MedlineTA>
            <NlmUniqueID>101083777</NlmUniqueID>
            <ISSNLinking>1582-1838</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bardet-Biedl syndrome</Keyword>
            <Keyword MajorTopicYN="N">ciliopathies</Keyword>
            <Keyword MajorTopicYN="N">genetic counselling</Keyword>
            <Keyword MajorTopicYN="N">minigene assay</Keyword>
            <Keyword MajorTopicYN="N">nonsense-mediated decay</Keyword>
            <Keyword MajorTopicYN="N">splicing variants</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28502102</ArticleId>
            <ArticleId IdType="doi">10.1111/jcmm.13147</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
